Who makes Volasertib, high dose, d1q3w?

Volasertib, high dose, d1q3w is developed by Boehringer Ingelheim.

What development phase is Volasertib, high dose, d1q3w in?

Volasertib, high dose, d1q3w is in Phase 1.

What are the side effects of Volasertib, high dose, d1q3w?

Common side effects include Leukopenia, Neutropenia, Thrombocytopenia, Constipation, Diarrhoea, Fatigue.

Last reviewed 2026-05-13 · How we verify

Volasertib, high dose, d1q3w

Boehringer Ingelheim · Phase 1 active Small molecule Quality 20/100

At a glance

Generic name	Volasertib, high dose, d1q3w
Sponsor	Boehringer Ingelheim
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

Leukopenia
Neutropenia
Thrombocytopenia
Constipation
Diarrhoea
Fatigue
Injection site reaction
Pyrexia
Cystitis
Contusion
Electrocardiogram QT prolonged
Periarthritis

Key clinical trials

BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Volasertib, high dose, d1q3w CI brief — competitive landscape report
Volasertib, high dose, d1q3w updates RSS · CI watch RSS
Boehringer Ingelheim portfolio CI